Skip to main content
Clinical Trials/NCT04585581
NCT04585581Active, not recruitingNot Applicable

Before the Beginning: Preconception Lifestyle Interventions to Improve Future Metabolic Health

Norwegian University of Science and Technology1 site in 1 country167 target enrollmentStarted: November 6, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
167
Locations
1
Primary Endpoint
Plasma glucose concentration

Study Overview

Brief Summary

The aim of this study is to investigate whether the combination of high intensity exercise and time restricted eating before and during pregnancy can reduce the risk of hyperglycaemia during pregnancy.

Detailed Description

Women who are planning a pregnancy will be recruited into a parallel groups randomised controlled trial where the intervention will consist of high intensity training and time-restricted eating. The intervention will continue throughout pregnancy. The investigators will assess whether this lifestyle intervention can effect maternal and offspring cardiometabolic health.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to 39 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • contemplating pregnancy within the next six months
  • At least one of the following criteria: BMI ≥ 25 < 40 kg/m2, gestational diabetes in a previous pregnancy, previous infant > 4.5 kg, fasting plasma glucose > 5.3 mmol/L, or Non-European ethnicity

Exclusion Criteria

  • On-going pregnancy
  • Trying to conceive ≥ 6 cycles at study entry
  • Known diabetes (type 1 or 2)
  • Shift work that includes night shifts > 2 days per week
  • Previous hyperemesis
  • Known cardiovascular diseases
  • High intensity exercise ≥ 2 hours/week the last 3 months
  • Habitual eating window ≤ 12 hours

Outcomes

Primary Outcomes

Plasma glucose concentration

Time Frame: Gestational week 28

Plasma glucose concentration after 2 h oral glucose tolerance testing (75 g glucose)

Secondary Outcomes

  • Head circumference of infant(Delivery)
  • Fat mass(Baseline, intervention week 8, gestational week 12 and 28)
  • Measured physical activity(From baseline and throughout the study period.)
  • Plasma glucose concentration(Gestational week 12)
  • HbA1c(Baseline, intervention week 8, gestational week 12 and 28)
  • Glucose(Baseline, intervention week 8, gestational week 12 and 28, and in cord blood (delivery))
  • Diet intake(Every 8 week throughout the trial.)
  • Insulin(Baseline, intervention week 8, gestational week 12 and 28, and in cord blood (delivery))
  • Cytokines(Baseline, intervention week 8, gestational week 12 and 28, and in cord blood (delivery))
  • Total cholesterol(Baseline, intervention week 8, gestational week 12 and 28)
  • Triglycerides(Baseline, intervention week 8, gestational week 12 and 28)
  • Infant bone mass(Within 72 hours of birth and after 6 weeks post delivery)
  • High density lipoprotein cholesterol(Baseline, intervention week 8, gestational week 12 and 28)
  • Low density lipoprotein cholesterol(Baseline, intervention week 8, gestational week 12 and 28)
  • Low density cholesterol(Baseline, intervention week 8, gestational week 12 and 28)
  • Psychological general well being(Baseline, intervention week 8, gestational week 12 and 28, and every 8 week until delivery or until the participant is excluded from the trial due to not conceiving within 6 months from baseline)
  • Time to pregnancy(From baseline to pregnancy (up to 36 weeks from enrollment))
  • Birth weight (infant)(Delivery)
  • Blood pressure (Infant)(Within 72 hours of birth and after 6 weeks post delivery)
  • Homocysteine(Baseline, intervention week 8, gestational week 12 and 28)
  • Continuous glucose monitoring(Baseline and 8 weeks intervention)
  • Chronotype(Baseline, intervention week 8, gestational week 12 and 28, and every 8 week until delivery or until the participant is excluded from the trial due to not conceiving within 6 months from baseline)
  • Apgar score(Delivery, after 1, 5 and 10 minutes)
  • ICU admission(Delivery)
  • Infant muscle mass(Within 72 hours of birth and after 6 weeks post delivery)
  • Insulin sensitivity(Baseline, intervention week 8, gestational week 12 and 28, and in cord blood (delivery))
  • Muscle mass(Baseline, intervention week 8, gestational week 12 and 28)
  • Psychological well-being(Baseline, intervention week 8, gestational week 12 and 28 and every 8 week throughout the trial.)
  • Cardiac function (Infant)(Within 72 hours of birth and after 6 weeks post delivery)
  • Adipokines (Adiponectin, Leptin, Ghrelin)(Baseline, intervention week 8, gestational week 12 and 28, and in cord blood (delivery))
  • Blood pressure(Baseline, intervention week 8, gestational week 12 and 28)
  • Birth length (infant)(Delivery)
  • Congenital malformation(Delivery)
  • Gestational age at birth(Delivery)
  • Length of stay at hospital(Delivery)
  • Infant total body mass(Within 72 hours of birth and after 6 weeks post delivery)
  • Infant fat mass(Within 72 hours of birth and after 6 weeks post delivery)
  • Infant hydration status(Within 72 hours of birth and after 6 weeks post delivery)
  • Total body mass(Baseline, intervention week 8, gestational week 12 and 28)
  • Visceral fat area(Baseline, intervention week 8, gestational week 12 and 28)
  • Cardiorespiratory fitness(Baseline and intervention week 8)
  • Self-reported physical activity(Baseline, intervention week 8, gestational week 12 and 28, and every 8 week until delivery or until the participant is excluded from the trial due to not conceiving within 6 months from baseline)
  • Sleep(Baseline, intervention week 8, gestational week 12 and 28, and every 8 week until delivery or until the participant is excluded from the trial due to not conceiving within 6 months from baseline)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials